-
-
-
-
-
-
-
This U.S. biotech stock is 'grossly undervalued', Bernstein says
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
-
-
-
-
-
-
Beam Therapeutics (BEAM) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
FDA Clears Way for Faster Personalized Gene Editing Treatments
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
-
-
-
-
-
-
Beam Therapeutics (BEAM) Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency
-
-
-
-
-
-
-
Beam Therapeutics (BEAM) Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency
-
429,992 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

